Commentary|Videos|November 18, 2026

Treating Male Breast Cancer: Women’s Data Only Go So Far

Fact checked by: Sabrina Serani

Dr Jose Pablo Leone on where extrapolating female breast cancer data to men holds up and where it falls short, from endocrine therapy to PARP inhibitors.

Male breast cancer accounts for under 1% of breast cancers, and because it is so uncommon, treatment decisions are often extrapolated from studies conducted in women. In this video, Jose Pablo Leone, MD, a medical oncologist at the Dana-Farber Cancer Institute and director of the program for breast cancer in men, explains where that approach holds up and where it falls short.

Leone notes that extrapolation is sometimes necessary and, in many situations, the only data available. However, he cautions that baseline risk, tumor biology, and physiology can differ between men and women, which may make applying results from female populations unhelpful or even unsafe. Endocrine therapy is a clear example. Because the physiology differs, the role of gonadal suppression in men can be very different than in postmenopausal women. Leone explains that aromatase inhibitors are often recommended with gonadal suppression in men because of a theoretical concern that using them alone may not sufficiently suppress estrogen levels. Although this has not been proven clinically, some reports suggest potentially worse outcomes in men treated with aromatase inhibitors without gonadal suppression.

He also discusses how he approaches newer agents when men have been excluded from or underrepresented in major trials. Leone says he looks for a biologic rationale before extrapolating. PARP inhibitors are one example, supported by data from prostate cancer showing efficacy in patients with germline BRCA1 or BRCA2 alterations. When the rationale is weaker, as with endocrine therapy, he urges added caution. Leone emphasizes the importance of dedicated studies in men. He notes that a study of antibody-drug conjugates reassuringly showed efficacy in men similar to that seen in women, although far fewer men than women have been treated with these agents.

Watch for his perspective on making treatment decisions in everyday practice when evidence specific to men is limited.


Related to this article